Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease: A Randomized Controlled Trial

The purpose of this study was to investigate the safety, tolerability, and efficacy of RVX-208, the first oral agent designed to enhance apolipoprotein (apo) A-I synthesis. No agent that selectively induces synthesis of apoA-I has reached an advanced stage of clinical development. A total of 299 sta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2011-03, Vol.57 (9), p.1111-1119
Hauptverfasser:	NICHOLLS, Stephen J, GORDON, Allan, JOHANSSON, Jan, WOLSKI, Kathy, BALLANTYNE, Christie M, KASTELEIN, John J. P, TAYLOR, Allen, BORGMAN, Marilyn, NISSEN, Steven E
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Apolipoprotein A-I - biosynthesis Apolipoprotein A-I - blood Apolipoprotein A-I - drug effects Apolipoproteins Atoms & subatomic particles Biological and medical sciences Cardiology Cardiology. Vascular system Cardiovascular disease Cholesterol Cholesterol, HDL - blood Cholesterol, HDL - drug effects Coronary Artery Disease - blood Coronary Artery Disease - drug therapy Coronary heart disease Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Drug dosages Female Follow-Up Studies Heart Heart attacks Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Lipids Lipoproteins Male Medical sciences Mortality Particle size Prospective Studies Proteins Quinazolines - administration & dosage Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!